- Home
- NMS vs CNTX Comparison
NMS vs CNTX Comparison
Compare NMS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- CNTX
- Stock Information
- Founded
- NMS 1993
- CNTX 2015
- Country
- NMS United States
- CNTX United States
- Employees
- NMS N/A
- CNTX N/A
- Industry
- NMS Finance Companies
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- NMS Finance
- CNTX Health Care
- Exchange
- NMS Nasdaq
- CNTX Nasdaq
- Market Cap
- NMS 71.2M
- CNTX 75.6M
- IPO Year
- NMS N/A
- CNTX 2021
- Fundamental
- Price
- NMS $11.81
- CNTX $0.97
- Analyst Decision
- NMS
- CNTX Strong Buy
- Analyst Count
- NMS 0
- CNTX 5
- Target Price
- NMS N/A
- CNTX $5.25
- AVG Volume (30 Days)
- NMS 12.0K
- CNTX 86.7K
- Earning Date
- NMS 01-01-0001
- CNTX 11-05-2025
- Dividend Yield
- NMS 4.11%
- CNTX N/A
- EPS Growth
- NMS N/A
- CNTX N/A
- EPS
- NMS N/A
- CNTX N/A
- Revenue
- NMS N/A
- CNTX N/A
- Revenue This Year
- NMS N/A
- CNTX N/A
- Revenue Next Year
- NMS N/A
- CNTX N/A
- P/E Ratio
- NMS N/A
- CNTX N/A
- Revenue Growth
- NMS N/A
- CNTX N/A
- 52 Week Low
- NMS $9.21
- CNTX $0.49
- 52 Week High
- NMS $12.18
- CNTX $2.59
- Technical
- Relative Strength Index (RSI)
- NMS 71.01
- CNTX 71.07
- Support Level
- NMS $11.68
- CNTX $0.81
- Resistance Level
- NMS $11.87
- CNTX $0.87
- Average True Range (ATR)
- NMS 0.11
- CNTX 0.05
- MACD
- NMS 0.04
- CNTX 0.00
- Stochastic Oscillator
- NMS 89.26
- CNTX 84.00
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.